Information from the abstract
To predict neoadjuvant chemotherapeutic outcomes, breast cancer organoids have been developed. However, low yields from small tissue specimens and the high cost of niche factor-enriched medium remain barriers to clinical translation. Here, breast cancer patient-derived microtumors (PDMs) from core needle biopsies and small tissue specimens were established using a modified culture protocol and an optimized fetal bovine serum (FBS)-based culture medium, achieving a 75% success rate (6 of 8 cases). PDM characteristics mostly agreed with the tissue origins, according to growth evaluation, histopathology, immunohistochemistry, and genetic profiling. As a proof of concept, PDMs were tested with neoadjuvant chemotherapy alongside the patients' treatment. Notably, the PDM results were positively correlated with the patient outcomes and were obtained within a clinically relevant time frame (∼2–3 weeks). Collectively, our protocol and FBS-based medium efficiently generate breast cancer PDMs from core needle biopsies and small tissue specimens, with promising potential to guide neoadjuvant chemotherapy decisions.
Why this record is monitored
This record has an Impact Signal of 74/100 based on recency, source, collaboration, and bibliographic signals. It prioritizes monitoring and is not a judgment of research quality.
Related topics: Cancer Cells and Metastasis · Breast Cancer Treatment Studies · 3D Printing in Biomedical Research
Thai researcher and institutional participation
Mooktapa Plikomol · Suphawat Laohawiriyakamol · Piyanun Wangkulangkul · Paramee Thongsuksai · Pokchon Khirilak · Ratsamaporn Nontikarn · Onpawee Phanthuvet · Karan Ulhaka · Pasarat Khongkow · Prince of Songkla University
Data limitations
This page is a bibliographic record based on abstract-level information, not a full analysis or quality assessment. Verify the DOI and original article before citation.